Astras nirsevimab meets endpoint. while two others approved in EU

Astras nirsevimab meets endpoint. while two others approved in EU | Financial News

Astras nirsevimab meets endpoint. while two others approved in EU | Financial News

(Alliance News) - AstraZeneca PLC said Monday that the Melody Phase III trial for nirsevimab met its primary endpoint. The pharma giant also noted its Tagrisso and Selumetinib treatments have been recommended for use in the EU. Nirsevimab is a long-acting antibody.

Live News Feed

News Feed featuring the top articles in the finance world from global publications such as Financial Times and the Economist.

Click here to view

Powered by © Neon Accelerator

From the Web

Tesla. Apple and Amazon Headline a Heavy Earnings Week

June 23, 2021 | From the web

More than a third of the S&P 500 are expected to report their quarterly results in the coming week. as companies detail how the reopening world is affecting their businesses.

Read More >

Shell Norco. Louisiana. hydrocracker partially shut to repair leak -sources

April 26, 2021 | From the web

Shell Norco. Louisiana. hydrocracker partially shut to repair leak -sources | Financial News

Read More >

LIVE MARKETS-Inflation chatter on front burner this earnings season

April 26, 2021 | From the web

LIVE MARKETS-Inflation chatter on front burner this earnings season | Financial News

Read More >

UK earnings. trading statements calendar – next 7 days

April 26, 2021 | From the web

UK earnings. trading statements calendar – next 7 days | Financial News

Read More >
Go to Top